This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: M33.0 (juvenile dermatomyositis) | Special Copayment Reduction: V137 (rare disease) |
| B. Synonyms | — |
| C. Adult onset | Likelihood of first onset in adulthood low — juvenile dermatomyositis (JDM) is by definition a pediatric disease with onset before age 18 (mainly 5–14 years). The mean age at diagnosis is 7–9 years, and new onset in adulthood does not fall under code M33.0 but is classified as M33.1 (other dermatomyositis) or M33.9. However, because JDM diagnosed in childhood does not adequately remit and transitions into adulthood in about 25–40% of cases, transition management of JDM is also important in adult rheumatology and internal medicine care. |
| 1. History | 1863, first description of dermatomyositis by Wagner → 1887, pediatric case reported by Unverricht → 1957, pediatric-adult classification proposed by Pearson → 1975, Bohan and Peter classification criteria published → 1995, Sugan revised JDM criteria → 2017, EULAR/ACR classification criteria for pediatric idiopathic inflammatory myopathies published. |
| 2. Causes | A multifactorial disease based on autoimmune vasculopathy. Genetic predisposition (HLA-DQA1*0501, etc.), environmental factors (infection: parvovirus B19, enterovirus; ultraviolet exposure) and immune abnormalities (type I interferon overactivity, vascular endothelial injury, autoimmunity of muscle and skin) act in combination. Unlike adult dermatomyositis, association with malignancy is rare. |
| 3. Genetics | HLA-DQA1*0501 is the strongest genetic susceptibility factor. HLA-DRB1*0301 (DR3) and HLA-DRB1*0101 (DR1) are also associated. TNF-α promoter -308A allele (associated with calcification and severe disease). Myositis-specific antibodies (MSA): anti-NXP2 (calcification, severe disease), anti-MDA5 (risk of interstitial lung disease), anti-TIF1γ (tumor-associated, rare in JDM), anti-Mi-2 and others are used to predict phenotype. |
| 4. General epidemiology | About 2–4 per million children per year (incidence). Prevalence about 2–4/100,000. Female:male = about 2:1. Age of onset mainly 5–14 years, mean 7–9 years. By race: higher incidence reported in Black and Hispanic children. JDM accounts for about 40–60% of pediatric idiopathic inflammatory myopathies in Korea. |
| 5. Pathophysiology | Small-vessel autoimmune vasculopathy is central. Complement-mediated vascular injury (C5b-9, MAC deposition) → capillary loss → ischemia and atrophy of muscle and skin. Type I interferon overactivity (pDC activation), MHC I-overexpressing muscle fibers → CD8+ T-cell infiltration. Skin lesions are explained by perivascular lymphocytic infiltration + basement membrane injury. |
| 6. Symptoms | Characteristic triad: proximal muscle weakness (difficulty climbing stairs and rising from chairs), Gottron papules (erythema over the finger joints), periorbital violaceous erythema (heliotrope rash). Fever, fatigue, weight loss (systemic), dysphagia and dysarthria (pharyngeal muscle involvement), calcinosis, arthralgia. Severe: interstitial lung disease (anti-MDA5), myocarditis. |
| 7. Signs | Proximal muscle weakness (Gowers sign), heliotrope rash, Gottron papules/sign, nailfold capillary abnormalities (dilation, hemorrhage, dropout), calcinosis (subcutaneous, fascial), cutaneous vasculitic macules, elevated muscle enzymes (CK, LDH, AST, aldolase), increased muscle signal on MRI. |
| 8. Screening | No screening of the general population. With proximal muscle weakness + skin lesions in a child: muscle enzymes (CK, LDH, ALT/AST, aldolase), ANA, myositis-specific antibodies (MSA/MAA panel), complete blood count, CRP/ESR. Then MRI (assessment of muscle edema), electromyography (EMG) and muscle biopsy for confirmation. |
| 9. Diagnosis | 2017 EULAR/ACR classification criteria: combination of proximal muscle weakness + characteristic skin findings (heliotrope rash, Gottron papules, Gottron sign) + ancillary tests (elevated muscle enzymes, MRI abnormalities, EMG abnormalities, muscle biopsy abnormalities). Muscle biopsy: perivascular inflammation, capillary damage, MHC-I overexpression on muscle fibers. Phenotype subdivided by ANA and myositis-specific antibodies (anti-NXP2, anti-MDA5, anti-TIF1γ, anti-Mi-2). |
| 10. Treatment | First-line: high-dose corticosteroids (oral or IV pulse) + methotrexate (MTX). Refractory/severe: intravenous immunoglobulin (IVIG), cyclosporine, MMF, azathioprine, hydroxychloroquine. Biologics: rituximab (refractory severe), abatacept, anti-IL-6 (tocilizumab). Calcinosis: diltiazem, colchicine, bisphosphonates. Rehabilitation and physical therapy essential. |
| 11. Prognosis | Course classified as monocyclic (remission within 2–3 years, about 40%) vs. polycyclic vs. chronic persistent (about 25%). Complications: calcinosis (about 10–30%), lipodystrophy, interstitial lung disease (anti-MDA5), joint contractures, growth impairment. 5-year survival about 98% or higher (developed countries). Long-term functional prognosis of patients transitioning to adult care is important. |
| 12. Prevention | No specific primary prevention. Sun protection (to prevent skin worsening due to photosensitivity), aggressive early treatment and maintenance of remission, regular follow-up (muscle enzymes, MRI, MSA), infection prevention (up-to-date vaccination, caution with live vaccines), physical therapy and rehabilitation, osteoporosis prevention (calcium, vitamin D), continued specialist follow-up during transition to adult care. |
| 13. References | Lundberg IE et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies. Ann Rheum Dis. 2017 … and 9 other papers |
Historical descriptions of dermatomyositis date back to the mid-19th century. The report by the German physician Ernst Leberecht Wagner in 1863 of a case with muscle inflammation is recognized as the first formal description, and around the same time Potain also reported a similar case. In 1887, the German neurologist Heinrich Unverricht first formalized the term 'dermatomyositis' for a syndrome with skin rash and muscle involvement, and systematically described several cases, including pediatric patients. From this period, dermatomyositis began to be recognized not as a simple muscle disease but as a complex disease with skin and systemic involvement.
In the early-to-mid 20th century, the clinical distinction between dermatomyositis and polymyositis gradually became clearer. In 1916, Stephan described clinical differences between children and adults, and with the introduction of steroid treatment in the 1940s–50s, systematic observation of treatment response took place. In 1957, Pearson proposed a classification dividing inflammatory myopathies into adult and pediatric forms, contributing to the concept of Juvenile Dermatomyositis (JDM) as an independent subtype.
The foundation of modern classification criteria is the inflammatory myopathy classification criteria published by Bohan and Peter in 1975. These criteria presented 5 items — ① proximal muscle weakness, ② elevated muscle enzymes, ③ EMG abnormalities, ④ muscle biopsy abnormalities and ⑤ characteristic skin findings — and were used as the standard for clinical research for decades. However, they had the limitation of not reflecting differences in clinical features in children, the role of myositis-specific antibodies (MSA) or new diagnostic methods such as MRI.
Since the 2000s, the discovery and characterization of myositis-specific antibodies (MSA) have been the most important advance in JDM research. Anti-NXP2 antibodies were found to be associated with calcinosis and severe muscle involvement in children with JDM, anti-MDA5 antibodies were associated with a subtype characterized by skin ulcers and interstitial lung disease, and anti-TIF1γ antibodies, a marker of tumor-associated dermatomyositis in adults, were reported to be associated with a chronic course in children. On this basis, in 2017 EULAR/ACR published new classification criteria for adult and pediatric idiopathic inflammatory myopathies, adopting a probability-based classification model that integrates adjustment items according to muscle biopsy results and myositis-specific antibodies. In Korea, registry studies and treatment standardization for JDM are being carried out through the Korean Society of Pediatric Rheumatology and related institutions.
In the history of treatment, therapy evolved from corticosteroid monotherapy to combination therapy with methotrexate (MTX) and intravenous immunoglobulin (IVIG), and since the 2010s the use of biologic and targeted synthetic agents such as rituximab, abatacept and Janus kinase (JAK) inhibitors has been expanding. The long-term prognosis of JDM and the problem of transition to adult care, as well as the prevention and treatment of calcinosis, remain important unresolved issues to date.
Juvenile dermatomyositis (JDM) is a multifactorial autoimmune disease whose pathophysiologic core is small-vessel autoimmune vasculopathy. It develops not from a single causative factor but from the combined action of genetic susceptibility, environmental triggers and immune dysregulation.
Genetic predisposition: the most strongly proven genetic susceptibility factor in JDM is the HLA-DQA1*0501 allele. This allele is consistently associated with increased JDM risk across multiple races and ethnic groups. The HLA-DRB1*0301 (DR3) and HLA-DRB1*0101 (DR1) genotypes are also associated with increased JDM risk. As a non-HLA genetic factor, the TNF-α promoter -308A allele has been reported, and studies show increased incidence of calcinosis and a chronic course in patients with JDM carrying this allele. In addition, interferon signaling pathway genes (IRF5, STAT4) and immunoregulatory genes are being studied as contributors to susceptibility.
Environmental factors: a seasonal clustering of onset has been reported, suggesting that infection is an important environmental trigger. JDM onset has been reported after infection with parvovirus B19, enterovirus, Coxsackievirus A/B and influenza virus. In particular, molecular mimicry between Coxsackievirus B and myositis-associated autoantigens such as histidyl-tRNA synthetase is proposed as one mechanism of immune activation. Ultraviolet exposure is also recognized as a trigger of skin lesions and disease exacerbation, and increased onset has been reported in seasons or regions with more sunlight. Unlike adult dermatomyositis, malignancy-associated occurrence is very rare in JDM.
Immunologic abnormalities: overactivation of type I interferons (IFN-α/β) is confirmed as the core immune mechanism of JDM. Expression of IFN-stimulated genes (the interferon signature) is markedly increased in the blood and muscle tissue of patients, which is related to activation of plasmacytoid dendritic cells (pDC). Complement-mediated vascular injury (C5b-9, membrane attack complex, MAC deposition) is observed in small vessels within muscle, resulting in capillary loss and ischemia and atrophy of muscle fibers. Infiltration of muscle and skin by CD4+ T cells, B cells and macrophages contributes to tissue injury. Increased MHC II expression on endothelial cells and excess inflammatory cytokines (IL-1β, IL-6, TNF-α) promote increased vascular permeability and tissue injury.
Myositis-specific antibodies (MSA) and pathogenesis: one or more myositis-specific antibodies (MSA) or myositis-associated antibodies (MAA) are detected in about 50–60% of patients with JDM. Whether these antibodies play a direct pathogenic role or are byproducts of the autoimmune process has not yet been fully elucidated, but the strong associations between each antibody type and specific clinical phenotypes (calcinosis, interstitial lung disease, skin ulcers, etc.) provide important clues for understanding the pathogenesis.
The genetics of juvenile dermatomyositis partly overlaps with that of adult dermatomyositis while having pediatric-specific features. It follows a polygenic inheritance pattern, and the best-characterized susceptibility genes to date are the HLA gene family.
HLA associations: HLA-DQA1*0501 is the susceptibility allele most consistently identified in patients with JDM of various races, increasing JDM risk about 3–4-fold. This allele is often accompanied by HLA-DRB1*0301 (DR3) or HLA-DRB1*0501 (DR5). HLA-DRB1*0101 (DR1) is also separately associated with increased JDM risk. HLA-DQA1*0201 and HLA-DQA1*0301 have been reported to be associated with a protective effect. In adult dermatomyositis, HLA-DRB1*0301 is also associated in anti-Jo-1 antibody-positive patients, but the antibody profile of JDM differs from that of adults.
Non-HLA genes: the TNF-α promoter -308A allele (rs1800629, G→A) increases TNF-α transcription, and studies show it is associated with increased incidence of calcinosis, a chronic course and more severe cutaneous vascular lesions in patients with JDM carrying it. IRF5 and STAT4 polymorphisms are related to overactive interferon signaling and explain genetic sharing with other autoimmune diseases. Polymorphisms of the immunoregulatory genes CTLA4, PTPN22 and IL-10 have also been reported to contribute to JDM susceptibility.
Association of myositis-specific antibodies (MSA) with genotype: MSA are central to distinguishing clinical subtypes of JDM. Anti-NXP2 (anti-MJ) antibody: one of the most common MSA in JDM (about 20–25%), strongly associated with severe calcinosis, muscle weakness and severe muscle atrophy. Associations with HLA-DQA1*0501 and DQB1*0301 have been reported. Anti-MDA5 antibody: associated with skin ulcers, palmar papules and interstitial lung disease (ILD), defining a subtype with a high risk of death due to rapid progression of ILD. It is reported more frequently in Asian children. Anti-TIF1γ (anti-p155/140) antibody: a marker of tumor-associated dermatomyositis in adults, but in JDM associated with extensive skin rash and a chronic course, with tumor association rare. Anti-Mi-2 antibody: associated with classic skin findings (heliotrope rash, Gottron papules), with a relatively good treatment response. Anti-Jo-1 antibody: common in adults but rare in JDM.
Significance of multiple autoantibody-genotype associations: because the MSA type strongly predicts the phenotype, MSA panel testing at JDM diagnosis plays an important role in risk stratification, planning of monitoring for organ involvement (especially ILD) and deciding treatment intensity. In MSA-negative JDM (about 40–50%), other mechanisms are thought to predominate, and research to discover new antibodies is actively underway. The application of genome-wide association studies (GWAS) in JDM is limited because, given the nature of rare pediatric diseases, large cohorts are difficult to assemble, and genetic research continues through international collaborative studies (EuroMyositis, CARRA, etc.).
Juvenile dermatomyositis (JDM) is a rare autoimmune disease occurring in childhood and is the most common subtype of idiopathic inflammatory myopathy in the pediatric age group. It occurs rarely worldwide, but it is of great clinical importance because it can cause long-term complications and functional impairment.
Incidence and prevalence: the annual incidence of JDM is reported as about 2–4 per million children, with a range of 1–7 per million children per year depending on the study. The prevalence is estimated at about 2–4 per 100,000 children. In North America and Europe, population-based studies report a gradually increasing incidence, but this may also be due to improved diagnostic awareness. Worldwide, JDM accounts for about 80% or more of pediatric diagnoses of idiopathic inflammatory myopathy (IIM) and needs to be distinguished from juvenile polymyositis (JDM 80%, juvenile polymyositis about 10–15%, other overlap syndromes).
Sex and age distribution: JDM occurs more often in females than males at a ratio of about 2:1, a less pronounced sex difference than in adult dermatomyositis (3:1). The median age of onset is about 7–9 years, most concentrated between 5 and 14 years. Onset before age 5 and at age 15 or older is relatively rare, and there are reports that the group with onset before age 5 has a more severe course. Some cases show a bimodal onset peak, and some studies report clustering of onset in spring to early summer.
Racial and ethnic differences: US and international cohort studies report that Black and Hispanic children have a higher incidence than white children (about 1.5–2-fold) and tend to show a more severe course (calcinosis, interstitial lung disease). In children of Asian descent, the frequency of the anti-MDA5 antibody-positive subtype is high, making monitoring for interstitial lung disease risk particularly important.
Epidemiology in Korea: systematic epidemiologic data on pediatric idiopathic inflammatory myopathies, including JDM, are limited in Korea. According to the Korean Society of Pediatric Rheumatology and single-center studies, JDM accounts for about 40–60% of pediatric idiopathic inflammatory myopathies, and anti-NXP2 and anti-MDA5 antibody-positive cases have also been reported in Korean pediatric patients with JDM. JDM is registered and managed in Korea as a rare disease under Special Copayment Reduction V137 (polymyositis/dermatomyositis group).
Transition to adult care: in about 25–40% of pediatric patients diagnosed with JDM, the disease persists into adulthood, requiring transition to adult rheumatology care. In transitioning patients, steroid-related complications (osteoporosis, growth impairment, cataracts), calcinosis, persistent muscle weakness and cardiopulmonary complications remain important management issues even in adulthood.
The pathogenesis of juvenile dermatomyositis centers on small-vessel autoimmune vasculopathy, with type I interferon overactivity, complement-mediated vascular injury, infiltration of autoreactive immune cells and ischemic injury of muscle and skin all involved in combination.
Type I interferon overactivity and vascular injury: an 'interferon signature', with markedly increased expression of type I interferons (IFN-α, IFN-β) and interferon-stimulated genes (ISG), is observed in the serum, blood cells and muscle tissue of patients with JDM. When plasmacytoid dendritic cells (pDC) are activated by self nucleic acids (especially dsDNA and ssRNA from apoptotic debris), they secrete large amounts of type I IFN, which damages vascular endothelial cells and activates other immune cells. Increased MHC II expression on vascular endothelial cells and upregulation of adhesion molecules (ICAM-1, VCAM-1) promote infiltration of immune cells into the vessel wall.
Complement-mediated vascular injury and muscle ischemia: the most characteristic pathologic finding of JDM is deposition of C5b-9 (membrane attack complex, MAC) in small vessels within muscle (especially capillaries and venules). This reflects vascular endothelial injury mediated by autoantibodies or by direct complement activation. Complement-mediated endothelial cell injury results in capillary dropout, markedly reducing vascular density within muscle tissue. The resulting muscle ischemia leads to muscle fiber atrophy and perifascicular atrophy, and perifascicular atrophy is the most characteristic pathologic finding on JDM muscle biopsy. In contrast to the direct attack on muscle fibers by CD8+ T cells observed in adult polymyositis, vascular lesions are more prominent in JDM.
Infiltration of autoreactive immune cells and cytokines: CD4+ T cells, B cells, plasma cells, macrophages and others infiltrate the perivascular and perimysial regions within muscle tissue. Inflammatory cytokines secreted by these immune cells, such as IL-1α, IL-1β, TNF-α, IL-6, IL-12, IL-15 and IFN-γ, contribute to muscle fiber injury and persistence of inflammation. Immature plasmacytoid dendritic cells (pDC) and monocytes/macrophages are the main producers of IFN-α, and they are concentrated around blood vessels within muscle.
Mechanism of skin lesions: the histopathology of the heliotrope rash and Gottron papules consists of vacuolar degeneration at the dermal-epidermal junction, perivascular lymphocytic infiltration, basement membrane thickening and mucin deposition. Ultraviolet exposure induces cell death in the skin and promotes exposure of nuclear antigens, worsening skin lesions. Nailfold capillary abnormalities (dilation, irregular loops, hemorrhage, avascular areas) reflect systemic small-vessel vasculopathy.
Mechanism of calcinosis: the exact mechanism of the subcutaneous and intramuscular calcinosis characteristic of JDM is still unclear. Necrosis of damaged muscle and fat tissue is understood to make the local environment alkaline, and phosphorylated proteins, acidic phospholipids and matrix vesicles released at the injury site are understood to promote calcium-phosphate crystal nucleation. The TNF-α -308A allele, treatment delay and persistent inflammatory activity are risk factors for calcinosis.
The clinical symptoms of juvenile dermatomyositis often appear gradually in children over weeks to months, but in some they present acutely. The key symptoms for diagnosis are proximal muscle weakness and characteristic skin rashes.
Systemic symptoms: fever (low-grade to high), weight loss, chronic fatigue and anorexia mainly appear early and may precede other symptoms by weeks to months. Irritability and lack of energy are prominent in children, and parents often complain that the child 'tires easily', 'has difficulty climbing stairs' or 'has trouble getting up in the morning'.
Muscle symptoms: proximal muscle weakness is the core symptom of JDM, mainly involving the proximal limb muscles (shoulder and pelvic girdles) and the neck flexors. Daily activities such as climbing stairs, rising from a chair, raising the arms, combing hair and washing the face become difficult, and Gowers' sign appears, in which the child pushes on the knees with the hands to stand up from the floor. When the pharyngeal muscles and neck flexors are involved, dysphagia, dysarthria and head lag occur, which are risk factors for aspiration pneumonia. Myalgia is reported in about 50–70%, and muscle tenderness to touch may also be present. Respiratory muscle involvement (respiratory failure) is rare but occurs in severe cases and, especially in anti-MDA5 antibody-positive patients, can combine with interstitial lung disease (ILD) to threaten respiratory function.
Skin symptoms: the most characteristic skin findings are the heliotrope rash and Gottron papules. The heliotrope rash is a violaceous to purple erythema appearing around both orbits (the eyelids), especially involving the upper eyelids and often accompanied by edema. Gottron papules are pink to violaceous papules or plaques appearing on the dorsal surfaces of the finger joints (MCP, PIP, DIP) and are a highly specific finding of JDM. Similar lesions (Gottron sign) may also appear on the extensor surfaces of the knees, elbows and ankles. Other findings include photosensitive erythema of the shoulder region (shawl sign), erythema of the V area (V-sign, neck and upper chest), scalp rash, cutaneous vasculitic macules of the lower limbs and nailfold capillary abnormalities. Skin ulcers occur particularly often in anti-MDA5 antibody-positive patients and suggest a worse prognosis.
Complication-related symptoms: calcinosis is a JDM-specific complication, deposited as hard nodules or plaques in the subcutaneous tissue, fascia and muscle, causing pain, skin ulcers, limited joint motion and infection. Arthralgia and arthritis accompany it in about 30–50%. In patients positive for antiphospholipid antibodies, the risk of thrombosis may be increased. Cardiac involvement (myocarditis, pericarditis, arrhythmias) is rare but increases the risk of death, and early detection by echocardiography is needed. Lipodystrophy appears as loss of subcutaneous fat and may lead to metabolic complications (insulin resistance, dyslipidemia).
The physical signs of juvenile dermatomyositis appear across various systems, centered on muscle and skin, and change with disease activity and disease duration.
Muscle strength examination findings: proximal muscle weakness is the most central sign on physical examination. Muscle strength is quantified with standardized manual muscle testing (MMT-8) and pediatric-specific tools (CMAS, Childhood Myositis Assessment Scale). Gowers' sign is the pattern of climbing up by pushing on the hands and knees when standing up from a lying position on the floor, reflecting proximal lower limb weakness. Neck flexor weakness is confirmed by a test of lifting the head in the supine position (head-lift test). In severe cases, reduced breath sounds and paradoxical abdominal breathing due to respiratory muscle weakness are observed.
Skin signs: Heliotrope rash: periorbital violaceous to purple erythema, especially involving the upper eyelids, possibly with edema. Gottron papules: pink to violaceous papules or scaly plaques on the dorsal finger joints, appearing on the fingers, knees and elbows. V-sign: photosensitive erythema of the neck and upper chest (V area). Shawl sign: erythema of the shoulders and upper back. Nailfold capillary abnormalities: capillary dilation, irregular loops, hemorrhages and avascular areas observed with a magnifier or capillaroscopy; associated with JDM activity. Calcinosis: hard nodules palpable in the skin or subcutaneous tissue, calcified opacities on X-ray. Skin ulcers (when anti-MDA5-positive): ulcers on the fingertips, elbows and at Gottron papule sites.
Laboratory findings: elevated muscle enzymes are a marker of active muscle inflammation. CK (creatine kinase) is elevated in about 70–80% but may be normal. LDH, AST, ALT and aldolase are also elevated. In active JDM with normal CK, LDH and aldolase may be more sensitive. ESR, CRP: elevated in the active phase. ANA: positive in about 50% (mainly low titer). Myositis-specific antibody (MSA) panel: positivity rates of anti-NXP2, anti-MDA5, anti-TIF1γ and anti-Mi-2 each differ. CBC: mild anemia, possible leukocytosis.
Imaging and electrophysiologic findings: MRI (muscle, T2 STIR sequence): confirms intramuscular edema (high signal intensity), fascial inflammation and fatty infiltration (chronic phase); useful for monitoring activity and selecting the biopsy site. Electromyography (EMG): myopathic pattern (short-duration, low-amplitude polyphasic motor unit potentials, increased spontaneous activity). Calcification is confirmed on plain X-ray or CT as subcutaneous, fascial and intramuscular opacities. Chest HRCT: essential for evaluating ILD (interstitial lung disease, mainly NIP or OP pattern) in anti-MDA5 antibody-positive patients.
Because of the rarity of the disease, general population screening for juvenile dermatomyositis is not recommended. A systematic testing approach is important in children clinically suspected of JDM, and early diagnosis and initiation of treatment have a decisive effect on long-term prognosis.
Clinical suspicion criteria: JDM is suspected and testing is pursued when a child has one or more of the following findings. ① Unexplained proximal muscle weakness (difficulty climbing stairs, Gowers' sign), ② periorbital violaceous erythema (heliotrope rash), ③ Gottron papules on the dorsal finger joints, ④ the combination of persistent fever + fatigue + skin rash. If any of these is present, muscle enzyme testing (CK, LDH, ALT/AST, aldolase) is performed without delay.
Initial screening test panel: muscle enzymes (CK, LDH, AST/ALT, aldolase): the most basic marker of muscle inflammatory activity. Even with normal CK, LDH and aldolase may be elevated. ANA (antinuclear antibody): positive at low titer in about 50%. Complete blood count (CBC), ESR, CRP: assessment of systemic inflammatory status. Biochemistry panel (liver function, kidney function, electrolytes): differentiation of muscle enzyme elevation and assessment of baseline organ function. Thyroid function tests: performed to differentiate muscle symptoms due to hypothyroidism (proximal muscle weakness, CK elevation).
Myositis-specific/associated antibody (MSA/MAA) panel: for diagnostic confirmation and phenotype prediction, an MSA/MAA panel including anti-NXP2, anti-MDA5, anti-TIF1γ, anti-Mi-2, anti-Jo-1, anti-PL-7, anti-PL-12, anti-EJ, anti-SRP, anti-SAE, anti-MBJ and others is performed early. In particular, when anti-MDA5 is positive, the risk of acute interstitial lung disease (ILD) is high, so immediate pulmonary function assessment and chest HRCT are needed. When anti-NXP2 is positive, a follow-up plan is established for the high-risk group for calcinosis.
Advanced tests: MRI (T2 STIR, thigh muscles or symptomatic muscles): assessment of muscle edema, fascial inflammation and fatty infiltration; confirmation of activity and guidance of the biopsy site. Electromyography (EMG): confirmation of the myopathic pattern, aid to differential diagnosis. Muscle biopsy: performed for confirmation when EMG is abnormal or when MSA is negative with abnormal MRI; because the sample must be taken from an actively inflamed site, MRI guidance is useful. Echocardiography: assessment of cardiac involvement (myocarditis, pericarditis, arrhythmias). Chest HRCT: ILD assessment when anti-MDA5 is positive or with respiratory symptoms. Swallowing contrast study: assessment of pharyngeal and esophageal function in dysphagia.
The diagnosis of juvenile dermatomyositis is made by integrating characteristic clinical findings, serum muscle enzymes and autoantibodies, and imaging, electrophysiologic and histopathologic tests. The new idiopathic inflammatory myopathy classification criteria published by EULAR/ACR in 2017 show improved classification performance over the earlier Bohan-Peter criteria in pediatric IIM, including JDM.
2017 EULAR/ACR classification criteria (pediatric application): these criteria are a probability-based model that applies different score weights depending on whether a muscle biopsy was performed and whether JDM antibodies are positive. Entry criteria are ① age at onset under 18 (for classifying JDM) and ② exclusion of known causes (malignancy, infection, drugs, etc.). Clinical variables include age at onset (under 18: +1.3 points), proximal muscle weakness (+0.7 points), heliotrope rash (+3.1 points), Gottron papules/sign (+2.0 points), facial erythema (+1.2 points), muscle MRI abnormalities (+1.2 points), insulin resistance (when accompanied by lipodystrophy), dysphagia/esophageal abnormalities (+0.7 points), sputum abnormalities/pulmonary fibrosis (in ILD) and arthritis (+0.7 points). When a muscle biopsy is performed, perifascicular atrophy, perivascular inflammation, muscle fiber necrosis/regeneration and MHC-I overexpression on muscle fibers provide additional diagnostic weight.
Muscle biopsy pathologic findings: the characteristic pathologic findings of JDM are as follows. ① Perifascicular atrophy: atrophy of muscle fibers at the periphery of the fascicles, highly specific for JDM. ② Perivascular infiltrate: perivascular infiltration of CD4+ T cells, B cells, plasma cells and plasmacytoid dendritic cells. ③ Vascular C5b-9 (MAC) deposition: MAC deposition in capillaries and small vessels confirmed by immunofluorescence or immunohistochemistry. ④ MHC-I overexpression on muscle fibers: increased MHC-I expression on the muscle fiber surface. ⑤ Muscle fiber necrosis and regeneration: observed in some active lesions. Infiltration of muscle fibers by CD8+ T cells, prominent in adult polymyositis, is relatively rare in JDM.
Ancillary diagnostic tools: nailfold capillaroscopy: confirms capillary abnormalities (dilation, hemorrhages, avascular areas); noninvasive and useful for monitoring activity. CMAS (Childhood Myositis Assessment Scale) or MMT-8: standardized assessment of muscle strength. Treatment response is monitored with disease activity measurement tools (PRINTO criteria, IMACS core set).
Differential diagnosis: the main diseases to differentiate from JDM include juvenile polymyositis (predominant CD8+ infiltration on biopsy, little vascular injury), congenital myopathies (onset in infancy, specific histochemical findings), muscular dystrophies (family history, specific gene variants), hypothyroidism (CK elevation, proximal muscle weakness), infectious myositis (viral, bacterial, parasitic), glycogen storage diseases, mitochondrial myopathies, mixed connective tissue disease, SLE and overlap syndromes.
The treatment goals for juvenile dermatomyositis are suppression of inflammation, recovery of muscle strength, improvement of skin lesions, prevention of complications (especially calcinosis and interstitial lung disease), minimization of steroid-related adverse effects and maintenance of normal growth and development. Treatment is individualized according to disease severity, MSA type and organ involvement.
First-line treatment — corticosteroids + methotrexate (MTX): the standard first-line treatment is the combination of high-dose corticosteroids and MTX. Corticosteroids are started as oral prednisolone (1–2mg/kg/day, maximum 60–80mg/day), and in severe disease or organ involvement (severe muscle weakness, dysphagia, cardiac involvement, ILD), intravenous methylprednisolone pulses (10–30mg/kg/day, maximum 1g, 3 consecutive days) are used first, followed by a switch to oral steroids. MTX (10–15mg/m²/week, subcutaneous or oral) is effective for steroid sparing and disease control and is currently the standard combination agent in first-line treatment of JDM. Folic acid supplementation is given concurrently to prevent MTX adverse effects (stomatitis, hepatotoxicity).
Hydroxychloroquine (HCQ): can be added early for control of skin lesions, arthritis and fatigue and for steroid sparing, and is particularly effective in patients with prominent skin lesions. The pediatric dose is 5mg/kg/day or less, and an annual ophthalmologic examination is needed.
Second-line treatment — MTX-refractory or severe disease: intravenous immunoglobulin (IVIG, 2g/kg once a month): effective for skin and muscle lesions and widely used in children due to excellent safety. However, high cost is a limiting factor. Cyclosporine (3–5mg/kg/day): used especially for MTX-refractory skin lesions and moderate to severe JDM. Mycophenolate mofetil (MMF, 20–30mg/kg/day): effective for skin lesions, muscle involvement and ILD. Azathioprine (AZA, 2–3mg/kg/day): used for maintenance treatment. Cyclophosphamide (CTX): used for severe ILD (especially anti-MDA5-positive acute ILD) and severe vasculitis.
Biologics: rituximab (anti-CD20): efficacy reported in refractory JDM, especially when B-cell-mediated pathogenesis predominates. Abatacept (CTLA4-Ig): improvement of muscle symptoms demonstrated in an adult phase 3 trial in refractory IIM; also used in children. Tocilizumab (anti-IL-6 receptor): efficacy in case reports and small studies. Baricitinib (JAK1/2 inhibitor): promising in small studies in JDM associated with the interferon signature; mechanism of blocking IFN signaling.
Treatment of calcinosis: diltiazem (calcium channel blocker), colchicine, bisphosphonates (promote resorption of calcification), warfarin (low dose), aluminium hydroxide and others are used in small studies. Efficacy varies, and no standard treatment has been established. Surgical removal is considered for large or infected calcinosis.
Rehabilitation and physical therapy: passive range of motion (passive ROM) is maintained even in the acute phase, and active strengthening exercises are gradually started in remission. Hydrotherapy is useful for improving joint movement without pain in children. Occupational therapy contributes to recovery of daily function.
The prognosis of juvenile dermatomyositis has improved greatly over recent decades with advances in early aggressive treatment. In modern multicenter cohort studies, 5-year survival reaches about 97–99%, but the persistence of long-term functional impairment, cumulative damage and reduced quality of life in many patients is a major clinical challenge.
Types of disease course: the natural course of JDM is broadly classified into three patterns. ① Monocyclic (about 35–40%): the most favorable course, reaching complete remission within 2–3 years after the first onset without relapse. ② Polycyclic (about 30–35%): a form with repeated remissions and relapses, requiring re-intensification of steroids and immunosuppressants at relapse. ③ Chronic continuous (about 25–30%): the poorest course, with persistent disease activity for years to decades; highest risk of cumulative damage and complications.
Poor prognostic factors: diagnostic delay (the longer the time from symptom onset to start of treatment, the greater the risk of calcinosis and joint contractures), anti-MDA5 antibody positivity (associated with interstitial lung disease and skin ulcers; risk of death with rapidly progressive ILD), anti-NXP2 antibody positivity (extensive calcinosis and muscle atrophy), the TNF-α -308A allele (calcinosis, chronic course), early incomplete response to treatment and persistent elevation of CK and LDH.
Calcinosis complications: calcinosis develops in about 10–30% of inadequately treated patients with JDM and causes limited joint function, recurrent skin ulcers and infections and chronic pain. Early aggressive treatment and rapid suppression of inflammation are the most effective strategies for preventing calcinosis.
Transition to adult care and long-term prognosis: in about 25–40% of children diagnosed with JDM, the disease persists into adulthood, and in these patients, steroid-related complications (osteoporosis, growth impairment, avascular osteonecrosis, cataracts, metabolic syndrome), lipodystrophy (insulin resistance, diabetes, dyslipidemia), joint contractures and cognitive decline can impair long-term quality of life. In transition care, structured transition programs are recommended so that adolescent patients can transition smoothly from pediatrics to adult rheumatology.
Follow-up plan: in the active phase, muscle enzymes, MSA levels (in some), muscle strength assessment (CMAS), skin lesions and steroid adverse effects are monitored every 4–6 weeks. Regular assessment continues every 3–6 months even while remission is maintained, and anti-MDA5-positive patients are followed periodically with pulmonary function tests and HRCT. For osteoporosis prevention, calcium and vitamin D supplementation and DEXA bone density testing (in patients on long-term steroids) are performed.
There is currently no specific primary prevention for the onset of juvenile dermatomyositis itself. However, secondary and tertiary prevention strategies to minimize complications after onset (calcinosis, joint contractures, interstitial lung disease, steroid-related adverse effects) and preserve long-term function are the core of clinical management.
Early diagnosis and start of treatment: in JDM, diagnostic delay significantly increases the risk of calcinosis, joint contractures, permanent muscle weakness and functional impairment. Therefore, prompt specialist referral and testing and early initiation of treatment in children suspected of JDM are the most important elements of secondary prevention. JDM awareness education for community physicians and parents contributes to reducing diagnostic delay.
Sun protection: to prevent worsening of skin symptoms and systemic flares, a broad-spectrum sunscreen of SPF 50 or higher is used daily, going out during hours of strong ultraviolet radiation is avoided and sun-protective clothing is worn. In patients with photosensitive skin findings, consistent practice of sun protection is essential for managing skin lesions.
Active maintenance of remission and continued immunosuppressive treatment: JDM has a high risk of relapse when treatment is stopped arbitrarily. Patients and caregivers are educated not to stop steroids or MTX without the specialist's instruction, and maintenance treatment continues for a certain period even after remission. Because calcinosis is strongly associated with active inflammation, rapid and complete suppression of inflammation is most important for preventing calcinosis.
Infection prevention and vaccination: because the risk of infection is increased in patients with JDM on immunosuppressive treatment, inactivated vaccines such as influenza (annually), pneumococcal and hepatitis B vaccines are kept up to date. Live vaccines such as varicella and MMR are in principle contraindicated in moderate or greater immunosuppression, so it is ideal to complete any needed live vaccines before starting immunosuppressive treatment. Education on hand hygiene and minimizing exposure to infection is important.
Growth, development and osteoporosis prevention: long-term steroid use can cause growth suppression and osteoporosis. Calcium (1,000–1,300mg/day) and vitamin D (600–1,000 IU/day) supplementation, weight-bearing exercise and a healthy diet are recommended. In patients on long-term steroids, regular DEXA bone density testing and whether to give bisphosphonates are considered. When growth impairment is severe, growth hormone treatment may be considered.
Continued physical therapy and rehabilitation: to prevent muscle weakness and joint contractures, passive joint exercises in the active phase and active strengthening and cardiopulmonary fitness exercises in remission are carried out continuously. Occupational therapy and notification of the school (with an educational support plan if needed) to support return to school and social participation are also important.
Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76(12):1955-1964. DOI: 10.1136/annrheumdis-2017-211468. PMID: 28595184.
Rider LG, Aggarwal R, Pistorio A, et al. 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis. Arthritis Rheumatol. 2017;69(5):911-923. DOI: 10.1002/art.40060. PMID: 28382778.
Feldman BM, Rider LG, Reed AM, Pachman LM. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008;371(9631):2201-2212. DOI: 10.1016/S0140-6736(08)60955-1. PMID: 18586077.
Papadopoulou C, McCann LJ. The vasculopathy of juvenile dermatomyositis. Front Pediatr. 2021;9:678250. DOI: 10.3389/fped.2021.678250. PMID: 34249816.
Tansley SL, Betteridge ZE, Shaddick G, et al. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset. Rheumatology (Oxford). 2014;53(12):2204-2208. DOI: 10.1093/rheumatology/keu273. PMID: 25009193.
Kobayashi I, Okura Y, Yamada M, et al. Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr. 2011;158(4):675-677. DOI: 10.1016/j.jpeds.2010.11.030. PMID: 21168007.
Deakin CT, Campanilho-Marques R, Simou S, et al. Efficacy and safety of cyclophosphamide treatment in severe juvenile dermatomyositis shown by marginal structural modeling. Arthritis Rheumatol. 2018;70(5):785-793. DOI: 10.1002/art.40418. PMID: 29361218.
Rouster-Stevens KA, Ferguson L, Morgan G, Pachman LM. Pilot study of etanercept in patients with refractory juvenile dermatomyositis. Arthritis Care Res (Hoboken). 2014;66(5):783-787. DOI: 10.1002/acr.22199. PMID: 24115708.
McCann LJ, Juggins AD, Maillard SM, et al. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland) — clinical characteristics of children recruited within the first 5 yr. Rheumatology (Oxford). 2006;45(10):1255-1260. DOI: 10.1093/rheumatology/kel099. PMID: 16632479.
Kim S, El-Hallak M, Dedeoglu F, et al. Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. Arthritis Rheum. 2009;60(6):1825-1830. DOI: 10.1002/art.24573. PMID: 19479882.